Similarly, based on the ORAL Surveillance trial, Ytterberg et al. published an analysis that compared the risk of major adverse cardiovascular events (MACEs) and malignancy (confirmed non-melanoma skin cancer) in a group of patients with RA treated with TOFA or a tumor necrosis factor (TNF) inhibitor. Here, TNF is linked to non-melanoma skin carcinoma.